Newsroom

Elektronenmikroskopische Aufnahme von Viruspartikeln des Grippeerregers Influenza.

News

Annual flu vaccines protect against severe infection, but they vary in efficacy and may not match the most virulent strains of the season. The reality of a universal flu vaccine, which would protect people from all strains, and ideally longer than a single season, remains elusive. This major roadblock is addressed by the INCENTIVE consortium, which is funded by the European Commission and coordinated at the Helmholtz Centre for Infection Research (HZI) by Prof. Carlos A. Guzman. Findings published in the Journal of Virology suggest that universal flu vaccines are coming closer.

10.09.2024

HZI Campus

Interview

A key focus at the Helmholtz Centre for Infection Research (HZI) and its sites like the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) is translating research findings into medical and pharmaceutical applications. Beyond scientific collaboration, the goal is to facilitate the transfer of technology and knowledge into practical and potentially commercial uses. Recently, the company MyxoTech has been founded as a HIPS spin-off. MyxoTech CEO Peter Sullivan explains what the new company is about and what it wants to achieve.

29.08.2024

HIPS

Group photo 4 scientists with a large cheque

News

Yesterday, the lighthouse project of the state of Lower Saxony reached its latest milestone: At the second portfolio conference of the Institute for Biomedical Translation (IBT) Lower Saxony, a high-caliber jury selected projects from the Helmholtz Centre for Infection Research and the Hannover Medical School that will receive funding of over 1.6 million euros. A total of 25 million euros are available to the IBT Lower Saxony until 2028 to accelerate the transfer of cutting-edge research in the life sciences in Lower Saxony and to bring it out into the world in the form of startups and entrepreneurial ideas.

28.08.2024

HZI Campus

Marco Galardini (left) and Maureen Obara in the lab.

News

Certain changes in the genetic material of pathogens can alter their ability to infect human cells or protect them better from defense by the immune system. Researchers were able to observe this effect particularly impressive in the SARS-CoV-2 virus. During the coronavirus pandemic, an interdisciplinary team at TWINCORE, Centre for Experimental and Clinical Infection Research in Hanover, investigated the interaction between pairs of mutations that might have triggered several of these changes in infectivity and immune escape. They have now published their findings in the journal Genome Biology. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH).

23.08.2024

TWINCORE

HZI Campus

Interview

The current outbreak of the Mpox virus originated in Central Africa. A first case has now been discovered in Europe. The WHO has declared the highest alert level. In an interview with Helmholtz, Fabian Leendertz, Director of the Helmholtz Institute for One Health (HIOH), puts the events in context.

23.08.2024

HIOH

News

The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine hesitation. In contrast, an innovative vector vaccine developed at the Helmholtz Centre for Infection Research (HZI) presents a compelling alternative. It elicits prolonged immune response in animal models, and maintains its efficacy over extended time. The concept employs an animal cytomegalovirus (MCMV; murine cytomegalovirus) as the vector that expresses and delivers the coronavirus spike protein information. Crucially, this vector poses no threat to humans, enhancing the vaccine's safety profile.

20.08.2024

HZI Campus

Back to the first page
...
19
20
21
22
...
149

HZI in the media

... , Stellvertretende Teamleiterin der Klinischen Epidemiologie am Helmholtz-Zentrum für Infektionsforschung (HZI), Braunschweig.

17.11.2025

Biermann Medizin

... und individueller Darmflora ab.

Forscher am Helmholtz-Zentrum für Infektionsforschung arbeiten bereits an der nächsten Generation ...

14.11.2025

Ad Hoc News

Klett-Tammen, Abteilung Epidemiologie (EPID), Helmholtz-Zentrum für Infektionsforschung (

HZI

), Braunschweig. Grundsätzlich sei auch die ...

13.11.2025

Deutsches Ärzteblatt

von Angios in Innsbruck & wissenschaftlicher Geschäftsführer Helmholtz-Zentrum für Infektionsforschung in Braunschweig/Deutschland), Klaus

13.11.2025

meinbezirk.at

... zu adressieren, suchen Forschende am HZI-Standort Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) im Rahmen ...

13.11.2025

Prophylaxe Journal

new antiviral medicines, says virologist Christian Sieben of the Helmholtz Centre for Infection Research in Germany.

Earlier in 2025, for

10.11.2025

The Press

Hochschule Hannover, die Universitätsmedizin Göttingen, das Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die KI-

07.11.2025

Heise online

... , Leiter der Forschungsgruppe Mikrobielle Wirkstoffe am Helmholtz-Zentrum für Infektionsforschung, zu bedenken. Das erste ...

07.11.2025

Leipziger Volkszeitung (LVZ)

Quelle: Pressemitteilung

HZI-Helmholtz Zentrum für Infektionsforschung ...

04.11.2025

LaborPraxis

Forschende des Helmholtz-Zentrums für Infektionsforschung und der Universität Würzburg entwickeln derzeit einen Kaugummi, der Grippeviren

04.11.2025

Arbeitsmedizin-Sozialmedizin-Umweltmedizin

... Vakzinologie und angewandte Mikrobiologie am Helmholtz-Zentrum für Infektionsforschung. Die M2-Membranproteinhemmer verhindern ...

02.11.2025

Augsburger Allgemeine

... etwas dran ist“, erklärt Biologe Marc Stadler vom Helmholtz-Zentrum für Infektionsforschung gegenüber der Barmer-Krankenkasse. „Es ...

30.10.2025

bild der wissenschaft

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.